Glooko Names Mark Clements, M.D., Ph.D. as Chief Medical and Strategy Officer

Audio By Carbonatix

PALO ALTO, Calif.--(BUSINESS WIRE)--May 19, 2025--

Glooko, a leading global diabetes data management company, today announced the appointment of Dr. Mark Clements as Chief Medical and Strategy Officer. Dr. Clements has served as Glooko’s fractional Chief Medical Officer since 2016 and will step into this expanded, full-time role designed to strategically integrate the company’s clinical vision, product roadmap, and data solutions to accelerate growth and innovation.

“Dr. Clements’ expertise as an endocrinologist, coupled with his deep experience in diabetes digital health, remote patient monitoring, data integration, AI and machine learning, and clinical trial design, uniquely positions him to align clinical insights directly with Glooko’s product and service offerings,” said Mike Alvarez, Chief Executive Officer of Glooko. “We are thrilled to have him in this expanded leadership role that will ensure Glooko continues to enhance health outcomes for people with diabetes, drive healthcare efficiencies, and solidify our market leadership through innovation grounded in clinical insight.”

In addition to his role as Chief Medical Officer of Glooko, Dr. Clements most recently served as Professor of Pediatrics at the University of Missouri-Kansas City (UMKC) School of Medicine, where he held the Endowed Chair in Endocrinology and Diabetes. At UMKC, Dr. Clements also held the role of Medical Director of the Pediatric Clinical Research Unit and the Diabetes Research Program and was Co-Principal Investigator of the TrialNet Clinical Center and Data Science Lead for the Type 1 Diabetes Exchange-Quality Improvement (T1DX-QI) initiative.

“As a long-time advisor to Glooko and an active user of the platform in my clinical practice, I’ve witnessed firsthand how Glooko helps clinical teams consistently deliver measurable improvements in diabetes care outcomes,” said Dr. Clements. “As we look to the future, precision engagement and population health insights will be key focuses of the company and our platform. We are investing in making it easier for healthcare providers to connect people with diabetes to the Glooko platform, reducing clinical staff burden, optimizing clinician time, helping them stay at the top of their scope of practice, and personalizing interventions. This is a pivotal moment for our company and for diabetes care delivery overall, and I am confident Glooko’s best-in-class technology will continue to improve how diabetes care is delivered.”

About Glooko

Glooko is focused on improving health outcomes for people with diabetes through our personalized, intelligent, connected care platform. Our proven technologies strengthen connections between patients and providers, and drive patient engagement and adherence via digital therapeutics, with more than 4.4 million people around the world who have used the Glooko platform. By seamlessly integrating with electronic health records (EHRs), providing a unified device ecosystem, and delivering actionable insights, Glooko aims to enhance clinical workflows and improve outcomes for people with diabetes and their care providers. For more information, please visit www.glooko.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250519839110/en/

CONTACT: Media Contact

Julia Fuller

(858) 692-2001

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: TECHNOLOGY MEDICAL DEVICES HOSPITALS DIABETES HEALTH TECHNOLOGY TELEMEDICINE/VIRTUAL MEDICINE SOFTWARE PRACTICE MANAGEMENT HEALTH

SOURCE: Glooko

Copyright Business Wire 2025.

PUB: 05/19/2025 08:00 AM/DISC: 05/19/2025 07:59 AM

http://www.businesswire.com/news/home/20250519839110/en